Ha C - Search Results

1

Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management.

Sands BE, Colombel JF, Ha C, Farnier M, Armuzzi A, Quirk D, Friedman GS, Kwok K, Salese L, Su C, Taub PR. Sands BE, et al. Among authors: ha c. Inflamm Bowel Dis. 2021 May 17;27(6):797-808. doi: 10.1093/ibd/izaa227. Inflamm Bowel Dis. 2021. PMID: 32870265 Free PMC article.

2

A nationwide 2010-2012 analysis of U.S. health care utilization in inflammatory bowel diseases.

van Deen WK, van Oijen MG, Myers KD, Centeno A, Howard W, Choi JM, Roth BE, McLaughlin EM, Hollander D, Wong-Swanson B, Sack J, Ong MK, Ha CY, Esrailian E, Hommes DW. van Deen WK, et al. Inflamm Bowel Dis. 2014 Oct;20(10):1747-53. doi: 10.1097/MIB.0000000000000139. Inflamm Bowel Dis. 2014. PMID: 25137415

3

Perioperative corticosteroid management for patients with inflammatory bowel disease.

Hicks CW, Wick EC, Salvatori R, Ha CY. Hicks CW, et al. Among authors: ha cy. Inflamm Bowel Dis. 2015 Jan;21(1):221-8. doi: 10.1097/MIB.0000000000000185. Inflamm Bowel Dis. 2015. PMID: 25208109 Review.

4

Presenteeism in Inflammatory Bowel Diseases: A Hidden Problem with Significant Economic Impact.

Zand A, van Deen WK, Inserra EK, Hall L, Kane E, Centeno A, Choi JM, Ha CY, Esrailian E, DʼHaens GR, Hommes DW. Zand A, et al. Inflamm Bowel Dis. 2015 Jul;21(7):1623-30. doi: 10.1097/MIB.0000000000000399. Inflamm Bowel Dis. 2015. PMID: 26070004

5

Medication Utilization and the Impact of Continued Corticosteroid Use on Patient-reported Outcomes in Older Patients with Inflammatory Bowel Disease.

Geisz M, Ha C, Kappelman MD, Martin CF, Chen W, Anton K, Sandler RS, Long MD. Geisz M, et al. Among authors: ha c. Inflamm Bowel Dis. 2016 Jun;22(6):1435-41. doi: 10.1097/MIB.0000000000000747. Inflamm Bowel Dis. 2016. PMID: 26978725 Free PMC article.

6

State of Adult Trainee Inflammatory Bowel Disease Education in the United States: A National Survey.

Cohen BL, Ha C, Ananthakrishnan AN, Rieder F, Bewtra M. Cohen BL, et al. Among authors: ha c. Inflamm Bowel Dis. 2016 Jul;22(7):1609-15. doi: 10.1097/MIB.0000000000000766. Inflamm Bowel Dis. 2016. PMID: 27306068 Free PMC article.

7

A Critical Review of Biosimilars in IBD: The Confluence of Biologic Drug Development, Regulatory Requirements, Clinical Outcomes, and Big Business.

Ha CY, Kornbluth A. Ha CY, et al. Inflamm Bowel Dis. 2016 Oct;22(10):2513-26. doi: 10.1097/MIB.0000000000000886. Inflamm Bowel Dis. 2016. PMID: 27564646 Review.

8

Reply.

Cohen BL, Ha C. Cohen BL, et al. Among authors: ha c. Inflamm Bowel Dis. 2016 Nov;22(11):E41. doi: 10.1097/MIB.0000000000000929. Inflamm Bowel Dis. 2016. PMID: 27618504 No abstract available.

9

Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis.

Deepak P, Alayo QA, Khatiwada A, Lin B, Fenster M, Dimopoulos C, Bader G, Weisshof R, Jacobs M, Gutierrez A, Ciorba MA, Christophi GP, Patel A, Hirten RP, Colombel JF, Rubin DT, Ha C, Beniwal-Patel P, Ungaro RC, Syal G, Pekow J, Cohen BL, Yarur A. Deepak P, et al. Among authors: ha c. Clin Gastroenterol Hepatol. 2021 Aug;19(8):1592-1601.e3. doi: 10.1016/j.cgh.2020.06.050. Epub 2020 Jul 3. Clin Gastroenterol Hepatol. 2021. PMID: 32629130 Free PMC article.

10

Development of Entrustable Professional Activities for Advanced Inflammatory Bowel Disease Fellowship Training in the United States.

Cohen BL, Gallinger ZR, Ha C, Holubar SD, Hou JK, Kinnucan J, Mahadevan U, Moss AC, Raffals LE, Regueiro M, Szigethy E, Wolf D, Dubinsky MC, Patel A, Shah BJ, Ehrlich OG, Hanauer SB. Cohen BL, et al. Among authors: ha c. Inflamm Bowel Dis. 2020 Aug 20;26(9):1291-1305. doi: 10.1093/ibd/izaa177. Inflamm Bowel Dis. 2020. PMID: 32820340

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,239 results

Search Page